Cov Tshuaj Tiv Thaiv Kab Mob Cancer Acalabrutinib: Kho Rau CLL / SLL / MCL - AASraw
AASraw ua rau Cannabidiol (CBD) hmoov thiab Hemp Roj tseem ceeb hauv qhov ntau!

Cov Tshuaj Tiv Thaiv Kab Mob Cancer Acalabrutinib

 

  1. Acalabrutinib Pab pawg Backgroud
  2. Kev Ntsuam Xyuas Acalabrutinib
  3. Kev Kho Mob Acalabrutinib (Siv rau)
  4. Acalabrutinib Kev Siv Tes Ua Ntawm Kev Ua
  5. Cov kev mob tshwm sim ntawm Acalabrutinib yog dab tsi?
  6. Acalabrutinib VS Ibrutinib
  7. Kev Tshawb Fawb: Acalabrutinib Txog Kev Kho Mob Mob Hlwb Hlwb Hlwb Mob (CLL)

 

Acalabrutinib Pab pawg Backgroud

Txog rau hnub tim, acalabrutinib tau siv rau hauv kev sim kawm kev kho mob B-Txhua, Myelofibrosis, Kheesxaws Menyuam, Ntau Yam Myeloma, thiab Hodgkin Lymphoma, thiab lwm yam.

Raws li Lub Kaum Hlis 31, 2017 FDA tau pom zoo Astra Zeneca qhov ncauj muab Calquence (acalabrutinib). Qhov no Bruton Tyrosine Kinase (BTK) inhibitor tau qhia rau kev kho mob ntawm cov qog ntshav qab zib, mob lymphocytic me me, thiab hauv cov neeg laus nrog Mantle Cell Lymphoma (MCL) uas twb tau txais kev kho mob tsawg kawg yog ib qho kev kho mob ua ntej.

Kuj hu ua ACP-196, acalabrutinib tseem raug suav hais tias yog ib tiam thib ob BTK inhibitor vim tias nws tau tsim los kom muaj lub zog thiab xaiv ntau dua li ibrutinib, raws li kev xav tau pom tsawg dua cov kev tsis zoo vim tiv thaiv kev cuam tshuam los ntawm cov hom phiaj tsis yog BTK.

Txawm li cas los xij, acalabrutinib tau txais kev pom zoo raws li FDA cov kev tso cai ceev, uas yog los ntawm kev lees paub tag nrho cov lus teb thiab kev pom zoo ua ntej kev pom zoo ntawm cov tshuaj uas kho mob hnyav lossis / thiab uas ua rau muaj kev kho mob tsis txaus ntseeg raws li kev ua kom tiav. Txuas ntxiv kev pom zoo rau acalabrutinib cov lus lees txais tam sim no tuaj yeem txuas ntxiv mus yog tias muaj pov thawj txuas ntxiv thiab cov lus piav qhia txog cov txiaj ntsig raug saib xyuas hauv kev sim kuaj mob.

Tsis tas li ntawd, FDA tau muab cov tshuaj no rau Kev Tshawb Xyuas Ua Ntej thiab Kev Tshawb Fawb Kev Tsim Kho. Nws tseem tau txais Orphan Tshuaj Tsim, uas muab kev txhawb zog los pab thiab txhawb txoj kev txhim kho cov tshuaj rau cov kab mob tsis tshua muaj. Lub sijhawm no, ntau tshaj li 35 qhov chaw kuaj mob thoob 40 lub tebchaws muaj ntau dua 2500 tus neeg mob tseem tab tom ua lossis tau ua tiav nrog kev hais txog kev tshawb fawb ntxiv rau kev nkag siab zoo thiab nthuav dav kev siv tshuaj kho mob acalabrutinib 5.

 

Acalabrutinib Xyuas

Acalabrutinib (CAS:1420477-60-6), uas ua lag luam nyob rau hauv lub npe ntawm Calquence® hauv Teb Chaws Asmeskas thiab Canada, yog lub cim thib ob me me ntawm cov tshuaj tiv thaiv molecule ntawm Bruton tyrosine kinase (BTK). Raws li txoj kev tswj hwm ntawm qhov ncauj, acalabrutinib khi rau thiab tsis pub cuam tshuam qhov kev cuam tshuam ntawm BTK uas txwv tsis pub muaj ob leeg ntawm B-cell thiab B-cell-mediated teeb meem. Qhov kev ua no ua rau muaj kev txwv tsis pub muaj kev loj hlob ntawm malignant B hlwb uas overexpress BTK. BTK yog qhov yuav tsum tau ua rau B-cell teeb meem, ua lub luag haujlwm tseem ceeb hauv B-cell kev loj hlob, thiab muaj ntau dhau los hauv B-cell malignancies, suav nrog CLL / SLL. Cov kev qhia ntawm BTK hauv cov qog hlwb yog txuam nrog kev nce ntxiv thiab kev muaj sia nyob ntev. Raws li lub sijhawm thib ob BTK inhibitor, acalabrutinib tau tsim los ua kom muaj txiaj ntsig ntawm BTK thiab txo qis-phiaj xwm kev ua haujlwm ntawm TEC (Tec Protein Tyrosine Kinase), EGFR (epidermal kev loj hlob tau receptor), thiab ITK (interleukin-2-inducible T- cell kinase). Thawj tiam BTK inhibitor, ibrutinib (Imbruvica), tsis muaj qhov tshwj xeeb no uas ua rau muaj qhov tshwm sim ntau dua ntawm qhov tshwm sim tsis zoo. Ntxiv nrog rau CLL / SLL, acalabrutinib tau txais kev pom zoo rau Mantle Cell Lymphoma (MCL). Lub Tebchaws National Center Center Network (NCCN) Cov Lus Qhia Sau cov acalabrutinib nrog lossis tsis muaj obinituzumab raws li thawj kab kev kho rau CLL / SLL raws li tsim nyog rau siv nyob rau hauv kev rov ua dua lossis refractory (R / R) CLL.

 

Acalabrutinib Kho (Siv rau)

Acalabrutinib yog siv los kho cov neeg mob mantle cell lymphoma (MCL; tus mob qog nqaij hlav sai sai uas pib hauv cov kab mob hauv lub nruab nrog cev) uas twb tau kho nrog tsawg kawg ib yam tshuaj kho mob.

Acalabrutinib tsuas yog siv ib leeg lossis nrog obinutuzumab (Gazyva) los kho mob ntsws lymphocytic (CLL; ib hom mob cancer uas pib cov qe ntshav dawb) thiab cov lymphocytic lymphoma me me (SLL: ib hom cancer uas pib hauv cov qe ntshav dawb).

Acalabrutinib nyob hauv chav kawm ntawm cov tshuaj hu ua kinase inhibitors. Nws ua haujlwm los ntawm kev thaiv qhov kev txiav txim ntawm cov protein tsis txaus ntseeg uas ua teeb liab rau cov cell mob qog hlav. Qhov no yuav pab kom tsis txhob kis mob hlwb.

 

Acalabrutinib Mechanism Of Action

Mantle Cell Lymphoma (MCL) yog ib hom muaj B-cell uas tsis yog Hodgkin lymphoma (NHL) uas tsis tshua pom muaj kev ua phem. Tom qab ntawd, rov tshwm sim ntau dua nyob rau MCL cov neeg mob thiab thaum kawg sawv cev rau kev muaj mob thaib tshwm sim.

Lymphoma tshwm sim thaum lub cev tiv thaiv kab mob lymphocytes loj tuaj thiab muaj ntau yam tshuaj tsis xwm yeem. Cov lymphocytes mob qog nqaij hlav no tuaj yeem mus rau ntau qhov chaw hauv lub cev, suav nrog cov qog ntshav, ntshav hno, pob txha pob txha, ntshav thiab lwm yam kabmob uas lawv tuaj yeem muaj ntau ntxiv thiab ua rau ib pawg (hu ua qog). Ib hom lymphocytes tseem ceeb uas tuaj yeem tsim kho qog ntshav qog ntshav yog lub cev B-lymphocytes (B-cells).

Bruton Tyrosine Kinase (BTK) yog ib qho kev qhia ntawm molecule ntawm B-cell antigen receptor thiab cytokine receptor pathways. Xws li BTK cov paib ua rau kom muaj kev ua haujlwm ntawm txoj hauv kev tseem ceeb rau B-cell nthuav dav, kev ua luam, chemotaxis, thiab kev nplaum ua kom tiav.

Acalabrutinib yog cov tshuaj tiv thaiv kab mob me me ntawm BTK. Ob leeg acalabrutinib thiab nws cov nquag metabolite, ACP-5862, ua kom tsim kev cog lus covalent nrog cov cysteine ​​residue (Cys481) hauv BTK qhov chaw nquag, ua rau muaj kev cuam tshuam ntawm BTK enzymatic kev ua ub no.Qhov txiaj ntsig, acalabrutinib tiv thaiv BTK-mediated kev ua haujlwm ntawm downstream. signaling protein CD86 thiab CD69, uas thaum kawg inhibits mal-B-cell loj hlob thiab kev muaj sia nyob.

Whereas ibrutinib feem ntau lees paub tias yog thawj-hauv-chav BTK inhibitor, acalabrutinib yog suav tias yog tiam thib ob BTK inhibitor feem ntau vim tias nws qhia tau qhov siab dua qhov xaiv thiab qhov inhibition ntawm lub hom phiaj ntawm BTK thaum muaj IC50 ntau dua lossis lwm qhov zoo tsis muaj kev txwv ntawm kinase cov haujlwm ntawm ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, thiab YES1.

Hauv cov txiaj ntsig, acalabrutinib tau tsim los kom muaj ntau yam thiab muaj zog dua li ibrutinib, txhua lub sijhawm qhia pom kev cuam tshuam tsawg dua - hauv kev tshawb xav - vim hais tias cov tshuaj tsis tshua muaj lub hom phiaj zoo.

AASraw yog lub chaw tsim khoom ntawm Acalabrutinib.

Thov nyem ntawm no rau cov ntaub ntawv hais: Hu rau peb

 

Cov kev mob tshwm sim ntawm Acalabrutinib yog dab tsi?

Acalabrutinib yuav ua rau muaj kev mob tshwm sim loj heev, suav nrog:

Cov mob hnyav tuaj yeem tshwm sim thaum kho mob Acalabrutinib thiab tuaj yeem ua rau tuag taus. Koj tus neeg muab kev pab kho mob yuav muab tshuaj rau yog tias koj muaj feem yuav kis tau tus kab mob ntxiv. Qhia koj tus kws kho mob sai li sai tau yog tias koj muaj cov cim lossis tsos mob ntawm tus mob, suav nrog ua npaws, ua daus no, lossis zoo li mob khaub thuas.

Los ntshav teeb meem (hemorrhage) tuaj yeem tshwm sim thaum kho mob Acalabrutinib thiab tuaj yeem mob hnyav thiab tuaj yeem ua rau tuag taus. Tej zaum koj yuav los ntshav ntau ntxiv yog tias koj tseem tab tom noj tshuaj noj kom ntshav ntxiv. Qhia koj tus neeg saib xyuas kev noj qab haus huv yog tias koj muaj cov cim lossis ntshav tawm ntawm lub cev, suav nrog cov ntshav hauv koj cov quav lossis cov quav dub (zoo li tar), tso zis liab lossis daj, tso zis tsis meej lossis los ntshav uas mob hnyav lossis koj tswj tsis tau, ntuav ntshav lossis ntuav uas zoo li thaj chaw kas fes, hnoos txog ntshav lossis txhaws ntshav, kiv taub hau, qaug zog, tsis meej pem, hloov pauv ntawm koj hais lus, mob taub hau uas siv sijhawm ntev, lossis doog lossis liab lossis liab doog nqaij tawv

Kev ua kom ntshav tsawg tsawg hauv cov ntshav. Cov ntshav tsawg zuj zus (ntshav dawb, ntshav hlwb thiab ntshav liab) muaj feem ntau nrog Acalabrutinib, tab sis tuaj yeem ua rau mob hnyav tau. Koj tus neeg muab kev pab saib xyuas kev noj qab haus huv yuav tsum tau kuaj ntshav los kuaj xyuas koj cov ntshav suav lub sij hawm kho nrog Acalabrutinib

Thib ob thawj cov qog nqaij hlav. Cov qog nqaij hlav tshiab tau tshwm sim hauv cov neeg thaum kho Acalabrutinib, suav nrog cov qog nqaij hlav tawv lossis lwm yam hauv nrog cev. Koj tus kws kho mob yuav kuaj xyuas koj cov tawv nqaij tawv nqaij thaum kho Acalabrutinib. Siv tiv thaiv tshav tiv thaiv thaum koj nyob sab nraum zoov thaum hnub ci.

Cov teeb meem plawv atherosclerosis (atrial fibrillation thiab atrial flutter) tau tshwm sim rau cov neeg kho Acalabrutinib. Qhia koj tus neeg saib xyuas kev noj qab haus huv yog tias koj muaj cov yam ntxwv hauv qab no: nrawm lossis ceev lub plawv dhia, kiv taub hau, tsaus muag, hnov ​​hauv siab, lossis ua pa luv.

Feem ntau cov kev mob tshwm sim ntawm Acalabrutinib suav nrog kev mob taub hau, raws plab, leeg mob thiab mob pob txha, mob lub ntsws ua pa, thiab doog ntshav.

Cov no tsis yog txhua txoj kev phiv los ntawm Acalabrutinib. Hu koj tus kws kho mob rau cov lus qhia kho mob txog cov kev mob tshwm sim. Koj yuav qhia txog tej kev phiv rau FDA ntawm 1-800-FDA-1088.

 

Acalabrutinib

 

 

Acalabrutinib V.S Ibrutinib

BTK ua lub luag haujlwm tseem ceeb hauv B-cell receptor teeb liab; acalabrutinib khi ruaj rau BTK thiab qhov kev tiv thaiv tsis zoo. Cov tshuaj tau tsim los ua qhov muaj peev xwm ntau dua BTK inhibitor, nyob rau hauv kev sim txo qee qhov kev kho mob-txo qhov muaj kuab lom feem ntau pom nrog ibrutinibCov. Raws li Dr. Brown, "Acalabrutinib yog BTK inhibitor kev xaiv rau cov neeg mob comorbidities, tshwj xeeb cov teeb meem mob plawv."

Cov txiaj ntsig ntawm cov ntaub ntawv zoo li zoo sib xws ntawm acalabrutinib thiab ibrutinib, txawm hais tias kev taug qab ntev nrog ibrutinib, Dr. Brown txuas ntxiv. Yog li, qhov sib txawv tseem ceeb ntawm cov tshuaj nyob hauv lawv cov ntawv qhia kev cuam tshuam. Ibrutinib feem ntau ua rau lub siab tsis zoo ua rau cov neeg mob laus dua thiab cuam tshuam nrog tus nqi siab ntawm atrial fibrillation thiab kub siab. Nws hais tias "Acalabrutinib muaj kev tiv thaiv zoo dua li ibrutinib, yog li kuv siv nws, tshwj xeeb tshaj yog rau cov neeg mob kuv laus," nws hais.

Cov tshuaj pom zoo hauv CLL, tau pom zoo thaum Lub Kaum Ib Hlis 2019, raws li cov ntaub ntawv kev nyab xeeb thiab ua tau zoo los ntawm kev tshuaj ntsuam me ntsis ntawm ELEVATE-TN kev sim ntawm cov neeg mob uas tsis tau kho dua CLL thiab ASCEND mus sib hais ntawm cov neeg mob uas rov mob lossis rov ua kom zoo dua CLL. Hauv ob qho kev sim, acalabrutinib ua rau pom kev muaj zoo dua-tsis muaj txoj sia nyob piv nrog cov qauv kho, thiab muaj qhov zam ua kom haum. Hauv ELEVATE-TN mus sib hais, tshwj xeeb, acalabrutinib ua ke nrog obinutuzumab thiab raws li kev kho mob txo qis txoj kev pheej hmoo ntawm tus kab mob kev loj hlob lossis tuag los ntawm 90% thiab 80%, feem.

Jeffleman, MD, Tus Thawj Coj ntawm Kev Tshawb Fawb ntawm Willamette Valley tau hais tias "Kev thev taus ntev tseem yog qhov teeb meem nyob rau ntawm thaj chaw kho tam sim no ntawm CLL. cancer Lub Koom Haum, Tus Thawj Saib Xyuas Kev Kho Mob Hematology Kev Tshawb Fawb rau US Oncology Network, thiab tus thawj coj ntawm ELEVATE-TN kev sim siab, hauv xov xwm tshaj tawm. "Hauv ELEVATE-TN thiab ASCEND cov kev sib piv sib piv [acalabrutinib] rau cov kev kho mob feem ntau, [acalabrutinib] tau qhia txog kev txhim kho hauv kev muaj txiaj ntsig hauv kev muaj sia-tsis muaj sia nyob hauv cov neeg mob hla ntau cov chaw, thaum tswj hwm nws txoj kev tiv taus thiab kev nyab xeeb."

 

Kev Tshawb Fawb: Acalabrutinib Txog Kho Mob ntsws roj ntshav ntev (CLL)  

(1) Mob ntsws roj ntshav ntev (CLL)

Mob ntsws lymphocytic (CLL), feem ntau ntawm cov neeg laus cov ntshav tawm ntawm caj dab, yog txha cajqaum neoplasm uas muaj cov hlwb monomorphic me B loj uas sib xyaw CD5 thiab CD23. Cov toj roob hauv pes ntawm kev kho ntawm CLL tau hloov ntau yam nyob rau xyoo tas los no. Cov tshuaj tsom rau cov protein nyob hauv B cell antigen receptor (BCR) txoj hauv kev, xws li ibrutinib, tau qhia txog kev txhim kho ntawm kev hloov kho dawb thiab tag nrho kev muaj sia nyob, suav nrog cov neeg mob uas muaj cov mob hnyav. Txawm hais tias cov tshuaj no tau hloov kho cov qauv kev kho mob hauv cov neeg mob CLL, kev kho mob thiab siv nrog ibrutinib tuaj yeem tau tsawg vim muaj kev phiv rau kev kho mob thiab kev kho mob ntsig txog cov tshuaj lom. Acalabrutinib, tiam thib ob thiab ntau dua Bruton tus tyrosine kinase (BTK) inhibitor, tau tsim los ua kom muaj txiaj ntsig zoo tshaj plaws thaum txo qis ibrutinib-cuam tshuam cov xwm txheej hypothesized los ua theem nrab rau ibrutinib qhov tawm ntawm kev cuam tshuam. Qhov kev tshuaj xyuas no yuav hais txog lub ntsiab kev txhim kho, kev soj ntsuam ua ntej, thiab kev sim tshuaj tseem ceeb uas tau qhia acalabrutinib qhov kev ua tau zoo thiab muaj cov tshuaj lom hauv CLL.

 

(2) Kev Kawm Ua Ntej ntawm Acalabrutinib hauv CLL

Ntau qhov kev kawm paub ua ntej qhia tau qhov txiaj ntsig ntawm acalabrutinib ntawm BTK inhibition. Thaum kuaj pom ntawm tib neeg cov ntshav, acalabrutinib muaj cov kab mob BTK inhibition raws li piv rau ibrutinib. Ibrutinib tau pom tias ua rau muaj kabmob apoptosis ntawm CLL ntau dua li piv rau acalabrutinib, uas tuaj yeem piav qhia los ntawm cov teebmeem ntawm ibrutinib. Acalabrutinib muaj tsawg dua qhov ua rau lub hlwb T zoo dua vim nws qhov xaiv ntau dua li piv rau ibrutinib.

Cov tshuaj los tiv thaiv cov qog ntawm acalabrutinib tau raug tshuaj xyuas nyob rau hauv ob tus qauv CLL murine: ib qho TCL1 kev hloov mus rau lwm tus hloov thiab xenografted tib neeg CLL qauv. Acalabrutinib tau pom tias inhibit BCR kev taw qhia thiab kev kho mob nrog acalabrutinib tau cuam tshuam txog kev muaj sia nyob ntau dua piv nrog cov nas tsis raug mob (nruab nrab 81 hnub vs 59 hnub, p = 0.02). Acalabrutinib tseem ua rau muaj qhov txo qis hauv kev nthuav tawm ntawm lub hlwb thiab tag nrho cov teeb meem qog nyob rau hauv spleen.

Acalabrutinib txoj kev sib cuam tshuam nrog tiv thaiv CD20 monoclonal cov tshuaj tiv thaiv kuj tau raug tshuaj xyuas. Ibrutinib tuaj yeem cuam tshuam nrog ntau ntawm cov kev ua ntawm kev ua ntawm anti-CD20 cov tshuaj tiv thaiv tshwj xeeb kev tiv thaiv kev tiv thaiv kev tiv thaiv kev tiv thaiv kab mob cellular cytotoxicity thiab phagocytosis uas tej zaum yuav txo lawv cov qog los tiv thaiv kev mob.Golay et al soj ntsuam qhov tshwm sim ntawm acalabrutinib ntawm cov tshuaj tiv thaiv-tiv thaiv cytotoxicity thiab phagocytosis thiab pom tias nws tsis cuam tshuam rau cov txheej txheem no, yuav tshwm sim vim qhov tsawg tshaj tawm ntawm lub hom phiaj ntawm acalabrutinib.Although ua ke ntawm acalabrutinib nrog cov tshuaj tiv thaiv CD20 monoclonal tsis tau kawm txog ib qho hauv vivo qauv, ntau ntu 2 thiab theem 3 cov kev tshawb fawb tseem tab tom ua tiav lossis tau ua tiav uas pom qhov ua tau ntawm acalabrutinib txuam nrog cov tshuaj tiv thaiv CD20 monoclonal tiv thaiv.

Lwm qhov sib xyaw acalabrutinib tau kawm tag nrho ob qho tib si hauv vitro thiab hauv vivo qauv. Acalabrutinib tau koom ua ke nrog PI3Kdelta inhibitor (ACP-319) nyob rau hauv tus qauv tua kabmob CLL thiab qhia tau txo qis ntau dua ntawm cov kabmob loj tuaj, NF-KB cov paib thiab kev qhia tawm ntawm BCL-xL thiab MCL-1 piv rau cov tshuaj tua kab mob.Blood kuaj tau los ntawm cov neeg mob CLL. tsis tau cuv npe hauv kev sim tshuaj kho tau kho nrog acalabrutinib thiab venetoclax.Qhov sib xyaw ua ke tau pom tias muaj ntau dua apoptosis thaum piv rau ib qho yeeb tshuaj ib leeg, qhia qhov sib thooj sib luag zoo ib yam li pom nrog ibrutinib thiab venetoclax. Tom qab ntawm vivo sim qhia pom tias muaj sia nyob ntev hauv cov nas kho nrog ob leeg acalabrutinib thiab venetoclax piv rau cov tshuaj ib leeg.

 

(3) cov lus xaus

Hauv cov ntsiab lus, cov kev tshawb fawb tau piav qhia tias acalabrutinib muaj kev ntxim siab tseem ceeb hauv kev kho mob ntawm CLL, ob qho tib si kev kho mob tsis zoo thiab rov ua mob refractory. Nws tsis paub meej tias qhov kev ua tau zoo yog sib npaug lossis zoo dua rau ibrutinib thiab cov kev tshawb fawb tseem nyob hauv ib qho kev sim los txuas ntxiv piv cov neeg sawv cev no. Txawm hais tias hom mob BTK-cuam tshuam txog kev lim ntshav xws li los ntshav lossis mob atrial fibrillation cov xwm txheej tsis tshua zoo, acalabrutinib puas muaj qhov tshwj xeeb AE profile, tshwj xeeb mob taub hau, uas yuav tsum tau ua tib zoo saib xyuas thiab kev txawj ntse hauv kev tswj hwm. Cov ntaub ntawv los ntawm cov kev tshawb fawb txuas ntxiv soj ntsuam kev sib xyaw ua ke nrog acalabrutinib yuav pab ntxiv rau nws txoj haujlwm tseem ceeb hauv kev tswj hwm ntawm CLL. Thaum kawg, nrog rau kev pom zoo los ntawm FDA, kev paub tiag tiag nrog acalabrutinib yuav pab ntxiv rau kev txhais cov ntsiab lus tshuaj lom neeg.

AASraw yog lub chaw tsim khoom ntawm Acalabrutinib.

Thov nyem ntawm no rau cov ntaub ntawv hais: Hu rau peb

 

reference

[1] Asmeskas Cov Khoom Noj thiab Tshuaj Yeeb Tshuaj. Txoj Haujlwm Orbis: FDA pom zoo acalabrutinib rau CLL thiab SLL. Muaj nyob ntawm https://www.fda.gov/drugs/ lwm yam- ntaub ntawv- tsis pom zoo-drugs/project-orbis-fda- pom zoo-acalabrutinib-cll-and-sll. Nkag mus rau Lub Plaub Hlis 29, 2020.

[2] Sharman JP, Banerji V, Fogliatto LM, li al. ELEVATE-TN: Theem 3 kawm txog kev mob acalabrutinib ua ke nrog obinutuzumab lossis ib leeg vs obinutuzumab ntxiv rau chlorambucil hauv cov neeg mob uas muaj kev kho mob-naive mob lymphocytic leukemia. Ntshav 2019; 134 (muab 1): 31.

[3] AstraZeneca Xov Xwm Tshaj Tawm. Calquence pom zoo hauv Asmeskas rau cov neeg mob laus lub cev mob qog ntshav ntshav. Muaj nyob ntawm https://www.astrazeneca.com/media-centre/press-releases/2019/calquence- Approved-in-the-us-for-adult-patients-with-chronic-lymphocytic-leukaemia-21112019.html. Nkag mus rau Lub Plaub Hlis 29, 2020.

[4] Goede V, Fischer K, Busch R, li al. Obinutuzumab ntxiv rau chlorambucil hauv cov neeg mob CLL thiab coexisting tej yam kev mob. N Engl J Med. Xyoo 2014; 370 (12): 1101–1110. doi: 10.1056 / NEJMoa1313984.

[5] Parikh SA, Muchtar E, Laplant B, li al. Ntu ntawm 2 txoj kev tshawb fawb sib piv acalabrutinib nrog lossis tsis muaj obinutuzumab hauv kev kho mob theem pib muaj kev pheej hmoo siab rau cov neeg mob uas muaj tus mob Lymphocytic Leukemia (CLL) lossis Me Lymphocytic Lymphoma (SLL). Ntshav. 2019; 134 (Ntxiv Ntxiv): 1. doi: 4306 / ntshav-10.1182-2019.

[6] Covey T, Gulranjani M, Cheung J, li al. Pharmacodynamic kev soj ntsuam ntawm acalabrutinib nyob rau hauv cov mob rov huam tuaj / rov ua dua tshiab thiab kho-cov neeg mob uas tsis muaj tus mob Chronic Lymphocytic Leukemia (CLL) hauv Kev Kawm 1/2 ACE-CL-001 Txoj Kev Kawm. Ntshav. 2017; 130 (Ntxiv Ntxiv 1): 1741. doi: 10.1182 / ntshav.V130.Suppl_1.1741.1741.

[7] Byrd JC, Brown JR, O'Brien S, li al. Ibrutinib tiv thaiv ofatumumab nyob rau yav tas los kho tus mob lymphoid leukemia. N Engl J Med. Xyoo 2014; 371 (3): 213–223. doi: 10.1056 / NEJMoa1400376.

[8] Woyach JA, Bojnik E, Ruppert AS, li al. Bruton tus mob tyrosine kinase (BTK) muaj nuj nqi yog qhov tseem ceeb rau kev txhim kho thiab nthuav dav ntawm cov qog ntshav ntawm cov qog ntshav (CLL). Ntshav. Xyoo 2014; 123 (8): 1207–1213. doi: 10.1182 / ntshav-2013-07-515361.

[9] Chiorazzi N, Rai KR, Ferrarini M. Ntaj mob lymphocytic. N Engl J Med. 2005; 352 (8): 804–815. doi: 10.1056 / NEJMra041720.

[10] Barr PM, Robak T, Owen C, li al. Txhawb kev ua tau zoo thiab cov ncauj lus kom ntxaws ntxaws soj qab taug qab ntawm thawj-kab ibrutinib kho nyob rau cov neeg laus uas muaj cov roj ntsha lymphocytic ntev: ncua cov qib 3 tau los ntawm RESONATE-2. Haematologica. 2018; 103 (9): 1502–1510. doi: 10.3324 / haematol.2018.192328.

[11] Herman SEM, Montraveta A, Niemann CU, li al. Cov Bruton Tyrosine Kinase (BTK) inhibitor ACP-196 qhia cov chaw kho mob hauv ob tus nas cov qauv ntawm cov ntshav muaj mob lymphocytic. Ntshav. Xyoo 2015; 126 (23): 2920. doi: 10.1182 / ntshav.V126.23.2920.2920.

 

 

1 yam koj nyiam
2059 Views

Koj kuj tseem nyiam

Lus raug kaw.